The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation

Jing, Chao; Li, Xingchen; Zhou, Mengqian; Zhang, Shengchi; Lai, Qingchuan; Liu, Dandan; Ye, Beibei; Li, Linqi; Wu, Yue; Li, Hong; Yue, Kai; Chen, Peng; Yao, Xiaofeng; Wu, Yansheng; Duan, Yuansheng; Wang, Xudong

doi:10.7150/thno.46109



Nanotheranostics 2024; 8(3): 380-400. [Abstract] [Full text] [PDF]

Nanotheranostics 2024; 8(3): 344-379. [Abstract] [Full text] [PDF] [PubMed] [PMC]

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

Global reach, higher impact

Full Text | PDF

Theranostics 2021; 11(12):5847-5862. doi:10.7150/thno.46109 This issue Cite

Research Paper

The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation

Chao Jing^1*, Xingchen Li^1*, Mengqian Zhou^1*, Shengchi Zhang^1,2*, Qingchuan Lai¹, Dandan Liu¹, Beibei Ye¹, Linqi Li¹, Yue Wu¹, Hong Li¹, Kai Yue¹, Peng Chen¹, Xiaofeng Yao¹, Yansheng Wu^1✉, Yuansheng Duan^1✉, Xudong Wang^1✉

1. Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin 300060, China.
2. Department of Ear, Nose and Throat, Tianjin 1st Centre Hospital, Tianjin 300192, China.
* These authors contributed equally to this work.

Citation:

Jing C, Li X, Zhou M, Zhang S, Lai Q, Liu D, Ye B, Li L, Wu Y, Li H, Yue K, Chen P, Yao X, Wu Y, Duan Y, Wang X. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation. Theranostics 2021; 11(12):5847-5862. doi:10.7150/thno.46109. https://www.thno.org/v11p5847.htm

Other styles

Abstract

Metastasis and chemoresistance are major causes of poor prognosis in patients with esophageal squamous cell carcinoma (ESCC), manipulated by multiple factors including deubiquitinating enzyme (DUB). DUB PSMD14 is reported to be a promising therapeutic target in various cancers. Here, we explored the antitumor activity of Thiolutin (THL), the PSMD14 inhibitor, as a new therapy strategy in ESCC.

Methods: Through 4-NQO-induced murine ESCC model, we investigated the expression of PSMD14 in esophageal tumorigenesis. Ubiquitin-AMC assay was performed to evaluate DUB activity of PSMD14 with THL treatment. The effect of THL on epithelial-to-mesenchymal transition (EMT), invasion, stemness and chemosensitivity was detected by using in vitro and in vivo experiments. Immunoprecipitation and in vivo ubiquitination assay were conducted to examine whether THL could impair the deubiquitination and stability of SNAIL regulated by PSMD14.

Results: Compared with normal esophageal epithelium, PSMD14 was upregulated in 4-NQO-induced murine esophageal epithelium dysplasia and ESCC tissues. THL could significantly weaken DUB activity of PSMD14. Furthermore, the results of in vitro and in vivo assays showed that THL efficiently suppressed motility and stemness and increased sensitivity to cisplatin in ESCC. Mechanically, THL impaired the interaction between PSMD14 and SNAIL, then promoted the ubiquitination and degradation of SNAIL to inhibit EMT which plays a crucial role in ESCC metastasis, stemness and chemosensitivity. TCGA database analysis revealed that high concomitant PSMD14/SNAIL expression predicted shorter overall survival in esophageal cancer.

Conclusion: Our findings demonstrate for the first time that suppression of PSMD14/SNAIL axis by THL could be a novel and promising therapeutic approach for ESCC clinical therapy.

Keywords: Esophageal squamous cell carcinoma, Thiolutin, PSMD14, SNAIL, EMT, Chemosensitivity.

Citation styles

APA

Jing, C., Li, X., Zhou, M., Zhang, S., Lai, Q., Liu, D., Ye, B., Li, L., Wu, Y., Li, H., Yue, K., Chen, P., Yao, X., Wu, Y., Duan, Y., Wang, X. (2021). The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation. Theranostics, 11(12), 5847-5862. https://doi.org/10.7150/thno.46109.

ACS

Jing, C.; Li, X.; Zhou, M.; Zhang, S.; Lai, Q.; Liu, D.; Ye, B.; Li, L.; Wu, Y.; Li, H.; Yue, K.; Chen, P.; Yao, X.; Wu, Y.; Duan, Y.; Wang, X. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation. Theranostics 2021, 11 (12), 5847-5862. DOI: 10.7150/thno.46109.

NLM

CSE

Jing C, Li X, Zhou M, Zhang S, Lai Q, Liu D, Ye B, Li L, Wu Y, Li H, Yue K, Chen P, Yao X, Wu Y, Duan Y, Wang X. 2021. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation. Theranostics. 11(12):5847-5862.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.